Shukla Akash, Vadeyar Hemant, Rela Mohamed, Shah Samir
Institute of Liver Diseases, HPB Surgery and Transplantation, Global Hospital - Superspeciality and Multiorgan Transplant Centre, 35, Dr. E. Borges Road, Hospital Avenue, Mumbai 400012, Maharashtra, India.
J Clin Exp Hepatol. 2013 Sep;3(3):243-53. doi: 10.1016/j.jceh.2013.08.004. Epub 2013 Sep 12.
Liver transplantation (LT) has evolved rapidly since the first successful liver transplant performed in1967. Despite a humble beginning, this procedure gained widespread acceptance in the western world as a suitable option for patients with end stage liver disease (ESLD) by the beginning of the 1980s. At present, approximately 25,000 liver transplants are being performed worldwide every year with approximately 90% one year survival. The techniques of living donor liver transplantation (LDLT) developed in East Asia in the 1990s to overcome the shortage of suitable grafts for children and scarcity of deceased donors. While deceased donor liver transplantation (DDLT) constitutes more than 90% of LT in the western world, in India and other Asian countries, most transplants are LDLT. Despite the initial disparity, outcomes following LDLT in eastern countries have been quite satisfactory when compared to the western programs. The etiologies of liver failure requiring LT vary in different parts of the world. The commonest etiology for acute liver failure (ALF) leading to LT is drugs in the west and acute viral hepatitis in Asia. The most common indication for LT due to ESLD in west is alcoholic cirrhosis and hepatitis C virus (HCV), while hepatitis B virus (HBV) predominates in the east. There is a variation in prognostic models for assessing candidature and prioritizing organ allocation across the world. Model for end-stage liver disease (MELD) is followed in United States and some European centers. Other European countries rely on the Child-Turcotte-Pugh (CTP) score. Some parts of Asia still follow chronological order of listing. The debate regarding the best model for organ allocation is far from over.
自1967年首次成功进行肝移植以来,肝移植(LT)发展迅速。尽管起步简陋,但到20世纪80年代初,该手术在西方世界已被广泛接受,成为终末期肝病(ESLD)患者的合适选择。目前,全球每年约进行25000例肝移植,一年生存率约为90%。20世纪90年代,东亚地区开发了活体肝移植(LDLT)技术,以克服儿童合适供肝短缺和脑死亡供体稀缺的问题。在西方世界,脑死亡供体肝移植(DDLT)占肝移植的90%以上,而在印度和其他亚洲国家,大多数移植是LDLT。尽管最初存在差异,但与西方项目相比,东方国家LDLT后的结果相当令人满意。世界各地需要肝移植的肝衰竭病因各不相同。导致肝移植的急性肝衰竭(ALF)最常见的病因在西方是药物,在亚洲是急性病毒性肝炎。西方因ESLD进行肝移植最常见的指征是酒精性肝硬化和丙型肝炎病毒(HCV),而在东方乙型肝炎病毒(HBV)占主导。世界各地在评估候选资格和确定器官分配优先级的预后模型方面存在差异。美国和一些欧洲中心采用终末期肝病模型(MELD)。其他欧洲国家依赖Child-Turcotte-Pugh(CTP)评分。亚洲一些地区仍按登记时间顺序进行。关于最佳器官分配模型的争论远未结束。